Bell & Brown Wealth Advisors LLC raised its holdings in Amgen, Inc. (NASDAQ:AMGN) by 163.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,715 shares of the medical research company’s stock after buying an additional 14,717 shares during the quarter. Amgen makes up approximately 1.9% of Bell & Brown Wealth Advisors LLC’s holdings, making the stock its 19th largest holding. Bell & Brown Wealth Advisors LLC’s holdings in Amgen were worth $4,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also bought and sold shares of the business. FMR LLC grew its holdings in shares of Amgen by 4.4% during the 3rd quarter. FMR LLC now owns 35,823,268 shares of the medical research company’s stock worth $7,425,805,000 after purchasing an additional 1,505,266 shares during the period. Oregon Public Employees Retirement Fund grew its holdings in shares of Amgen by 20,103.6% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,424,215 shares of the medical research company’s stock worth $161,000 after purchasing an additional 31,268,677 shares during the period. Capital International Investors grew its holdings in shares of Amgen by 301.4% during the 3rd quarter. Capital International Investors now owns 11,093,182 shares of the medical research company’s stock worth $2,299,506,000 after purchasing an additional 8,329,861 shares during the period. Capital World Investors purchased a new stake in shares of Amgen during the 3rd quarter worth about $952,900,000. Finally, Renaissance Technologies LLC grew its holdings in shares of Amgen by 8.2% during the 3rd quarter. Renaissance Technologies LLC now owns 4,115,145 shares of the medical research company’s stock worth $853,028,000 after purchasing an additional 311,545 shares during the period. Institutional investors own 78.13% of the company’s stock.
A number of analysts have recently issued reports on AMGN shares. Zacks Investment Research upgraded Amgen from a “hold” rating to a “buy” rating and set a $225.00 target price for the company in a report on Monday, January 14th. Jefferies Financial Group reiterated a “buy” rating and set a $220.00 target price on shares of Amgen in a report on Tuesday, December 4th. Morgan Stanley reiterated a “buy” rating and set a $213.00 target price on shares of Amgen in a report on Tuesday, December 4th. Goldman Sachs Group reiterated a “buy” rating and set a $232.00 target price on shares of Amgen in a report on Tuesday, December 4th. Finally, Oppenheimer set a $224.00 target price on Amgen and gave the stock a “buy” rating in a report on Sunday, January 27th. Twelve analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $209.79.
Amgen stock opened at $191.24 on Friday. The company has a market cap of $116.84 billion, a P/E ratio of 13.28, a P/E/G ratio of 2.25 and a beta of 1.21. The company has a current ratio of 2.79, a quick ratio of 2.57 and a debt-to-equity ratio of 2.36. Amgen, Inc. has a one year low of $163.31 and a one year high of $210.19.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, January 29th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.26 by $0.16. The firm had revenue of $6.23 billion for the quarter, compared to analyst estimates of $5.88 billion. Amgen had a return on equity of 66.74% and a net margin of 35.35%. During the same period in the previous year, the company posted $2.89 EPS. Sell-side analysts expect that Amgen, Inc. will post 13.97 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be given a dividend of $1.45 per share. This represents a $5.80 annualized dividend and a yield of 3.03%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 40.28%.
In related news, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $188.88, for a total transaction of $377,760.00. Following the transaction, the director now directly owns 14,988 shares of the company’s stock, valued at approximately $2,830,933.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.27% of the company’s stock.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
See Also: Analyst Ratings Trading
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.